Phathom Pharmaceuticals Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.32%.
Did PHAT Beat Earnings? Q4 2025 Results
Phathom Pharmaceuticals delivered a standout fourth quarter, posting a loss of just $0.08 per share against a consensus estimate of $0.42, a beat of 80.95%, while revenue of $57.58 million edged past the $57.20 million estimate and nearly doubled the year-ago figure, reflecting 94.1% growth year-over-year. The primary engine behind the outperformance was the accelerating commercial launch of VOQUEZNA, which saw approximately 273,000 prescriptions filled in Q4 alone, a 24% sequential increase that has pushed total prescriptions past 1.1 million. Equally notable was the company's expense discipline, with operating costs falling to $55.87 million from $85.27 million in the prior-year quarter, tightening net cash usage to roughly $5.20 million for the period. A $130 million equity offering and a restructured term loan have since bolstered the balance sheet to approximately $190 million in cash, reinforcing management's guidance for FY 2026 net revenues of $320 million to $345 million and operating profitability, excluding stock-based compensation, beginning in Q3 2026, prompting at least one analyst to raise their price target on the stock.
- VOQUEZNA prescriptions grew 24% quarter over quarter to approximately 273,000 in Q4
- Covered prescriptions grew 21% in Q4 and continue to be the primary driver of revenue
- Over 1.1 million total VOQUEZNA prescriptions filled to date
- Operating expense discipline with Q4 operating expenses declining to $55.9 million from $85.3 million year-over-year
- Net cash usage improved 64% sequentially from approximately $14 million in Q3 to approximately $5.2 million in Q4
“We are pleased with our continued growth throughout 2025, leveraging the efficiency of our GI-focused strategy. Revenue increased significantly over the last three quarters. In the fourth quarter, we realigned our sales organization and enter 2026 with a stronger sales team and marketing initiatives designed to deepen engagement and increase prescribing for GERD across gastroenterologists.”
Phathom Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
For FY 2026, Phathom is guiding to net revenues of $320–$345 million (including approximately $17–$20 million from a classification change), gross-to-net of 55–59%, gross margin of approximately 80%, and non-GAAP operating expenses (excluding stock-based compensation) of $235–$250 million. The company expects to achieve operating profitability (excluding stock-based compensation) beginning in Q3 2026 and for the full year 2026. Cash flow positivity is anticipated in 2027. The Phase 2 pHalcon-EoE-201 trial topline results are expected in 2027.
PHAT YoY Financials
PHAT Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.